Traws Pharma, Inc.
TRAW
$1.77
$0.1156.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.00K | 56.00K | 57.00K | 57.00K | 56.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.00K | 56.00K | 57.00K | 57.00K | 56.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 57.00K | 56.00K | 57.00K | 57.00K | 56.00K |
| SG&A Expenses | 2.75M | 3.48M | 3.48M | 1.98M | 3.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.26M | 5.33M | 8.59M | 5.94M | 5.27M |
| Operating Income | -5.20M | -5.28M | -8.54M | -5.88M | -5.21M |
| Income Before Tax | 21.49M | -29.92M | -8.48M | -123.14M | -4.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.49M | -29.92M | -8.48M | -123.14M | -4.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.49M | -29.92M | -8.48M | -123.14M | -4.98M |
| EBIT | -5.20M | -5.28M | -8.54M | -5.88M | -5.21M |
| EBITDA | -5.20M | -5.28M | -8.53M | -5.88M | -5.21M |
| EPS Basic | 2.17 | 26.60 | -8.81 | -121.63 | -5.92 |
| Normalized Basic EPS | 1.93 | -6.07 | -5.51 | -3.51 | -3.70 |
| EPS Diluted | 2.09 | 26.60 | -8.81 | -121.63 | -5.92 |
| Normalized Diluted EPS | 1.86 | -6.07 | -5.51 | -3.51 | -3.70 |
| Average Basic Shares Outstanding | 6.97M | 3.08M | 961.50K | 1.01M | 841.70K |
| Average Diluted Shares Outstanding | 7.22M | 3.08M | 961.50K | 1.01M | 841.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |